一、API接口地址                                                                                 

url: https://chatai.dyg.com.cn/api/v1/chat/completions

key: fastgpt-mKIZmHlk5l9WSEuyMlqfqpEXEb4OzTc0nd5zFJp3DAWX0zxbGddjySq3eC

      # hec_rag_formulation（制剂处方工艺知识库）
      curl -X POST \
        https://chatai.dyg.com.cn/api/v1/chat/completions \
        -H "Content-Type: application/json" \
        -H "Authorization: Bearer fastgpt-
      mKIZmHlk5l9WSEuyMlqfqpEXEb4OzTc0nd5zFJp3DAWX0zxbGddjySq3eC" \
        -d '{
          "stream": true,
          "messages": [
           {"role": "user", "content": "这是一个模拟开场白"},
           {"role": "assistant", "content": "\n我是一位制剂专家。"},
           {"role": "user", "content": "分析化合物C[C@H]1[C@@H]
      (O)O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]1[C@@]24OO3"}
          ]
        }'
      

      curl -X POST \
        https://chatai.dyg.com.cn/api/v1/chat/completions \
        -H "Content-Type: application/json" \
        -H "Authorization: Bearer fastgpt-
      mKIZmHlk5l9WSEuyMlqfqpEXEb4OzTc0nd5zFJp3DAWX0zxbGddjySq3eC" \
        -d '{
          "stream": true,
          "messages": [
            {"role": "user", "content": "This is a sample opening 
      dialogue"},
            {"role": "assistant", "content": "\nI am a pharmaceutical 
      formulation expert."},
            {"role": "user", "content": "Please analyze the chemical 
      structure of the compound C[C@H]1[C@@H]
      (O)O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]1[C@@]24OO3."}
          ]
        }'
        
      # hec_rag_pharmaceutics（药剂学综合知识库）
      curl -X POST \
  https://chatai.dyg.com.cn/api/v1/chat/completions \
  -H "Content-Type: application/json" \
  -H "Authorization: Bearer fastgpt-
mKIZmHlk5l9WSEuyMlqfqpEXEb4OzTc0nd5zFJp3DAWX0zxbGddjySq3eC" \
  -d '{
    "stream": true,
    "messages": [
     {"role": "user", "content": "这是一个模拟开场白"},
     {"role": "assistant", "content": "\n我是一位制剂专家。"},
     {"role": "user", "content": "某API化学结构为`Cc1cn2nc(-
c3cc(=O)n4cc(N5CCNC6(CC6)C5)ccc4n3)cc(C)c2n1`，请分析该结构，并给出其药
物通用名。"}
    ]
  }'


curl -X POST \
  https://chatai.dyg.com.cn/api/v1/chat/completions \
  -H "Content-Type: application/json" \
  -H "Authorization: Bearer fastgpt-
mKIZmHlk5l9WSEuyMlqfqpEXEb4OzTc0nd5zFJp3DAWX0zxbGddjySq3eC" \
  -d '{
    "stream": true,
    "messages": [
      {"role": "user", "content": "This is a sample opening 
dialogue"},
      {"role": "assistant", "content": "\nI am a pharmaceutical 
formulation expert."},
      {"role": "user", "content": "What are the advantages of gas 
dispersion dosage forms?"}
    ]
  }'
     # 响应格式说明
     #运行
     data: {"id":"","object":"","created":0,"model":"","choices":
     [{"delta":
     {"role":"assistant","content":"14"},"index":0,"finish_reason":null}
     ]} 
     #结束
     data: {"id":"","object":"","created":0,"model":"","choices":
     [{"delta":
     {"role":"assistant","content":null},"index":0,"finish_reason":"stop
     "}]}

二、模型简介及参数说明                                                               

HEC-PharmAI模型服务于新药研发与药物制剂研究领域，旨在通过人工智能大模型技术为
研发人员提供药剂学知识分析与制剂处方工艺的初步方案设计。其核心功能包括：结构化文
本转换与向量数据库构建、hec_rag知识库检索增强模块，辅以baseline_rag/graph_rag测试
模块和ragas_benchmark评估框架。整合药剂学专著、专利、论文等数据，用户输入药剂学
问题与化合物SMILES即可获取处方设计。支持本地命令行运行和OpenAI兼容API，可快速
部署网页应用。

模型特点：

        支持模型 : DeepSeek-R1（默认）, deepseek-chat, deepseek-reasoner, Qwen3系
        列
        语言支持 : 中文/英文双语
        知识库：制剂处方工艺知识库、药剂学综合知识库。根据知识库的不同分为两个模
        型
        响应特点 : 流式输出，包含思考过程

参数说明：

        --database：向量数据库路径
        --embedding_model：嵌入模型路径
        --reranker_model：重排序模型路径
        --model_name：LLM 模型名称，默认为DeepSeek-R1
        --context_messages：上下文消息文件，即前端输入的信息
        --pop_first：忽略首轮QA （注：使用FastGPT做前端时会使用这个命令忽略开场
        白，即忽略 {"role": "user", "content": "这是一个模拟开场白"},  {"role": "assistant", 
        "content": "\n我是一位制剂专家。"}）
三、UI设计建议                                                                                  

         支持中英文切换
         加载状态 : 显示"思考中..."
         流式显示 : 逐字显示回答内容
         引用展示 : 底部显示参考文献列表
         历史记录 : 支持对话上下文保存

参考如下：



四、测试用例                                                                                    

      1. hec_rag_formulation（制剂处方工艺知识库）-中文
      单轮对话：
      （1）请为比索洛尔（Bisoprolol）设计片剂，包括基于其特性的剂量，并以表格形式展示设
      计的配方和剂量，同时解释设计的原因（包括配方和工艺）。
      （2）请设计以加奈索酮（Ganaxolone）为活性成分的药物新剂型，以表格形式展示设计的配
      方和剂量，同时解释设计的原因（包括配方和工艺）。
      多轮对话：
      （1）某 API 化学结构为Cc1cn2nc(-
      c3cc(=O)n4cc(N5CCNC6(CC6)C5)ccc4n3)cc(C)c2n1，请分析该结构，并给出其药物
      通用名。
      （2）分析利司扑兰（Risdiplam）的理化性质、构效关系及药理（药效学和药代动力学）作
      用。
      （3）参考利司扑兰（Risdiplam）的现有处方，为其设计口崩片剂型，包括基于其特性的剂
      量，并以表格形式展示设计的配方和剂量，解释设计理由。
      （4）参考利司扑兰（Risdiplam）治疗脊髓性肌萎缩症的制剂工艺专利（WO/US），描述新
      处方的工艺过程，突出关键参数。
      

      2. hec_rag_formulation（制剂处方工艺知识库）-英文
      Single-turn dialogue:
(1) Please design a tablet formulation for Bisoprolol, including 
the dosage based on its characteristics. Present the designed 
formulation and dosage in a table format, and explain the rationale 
behind the design (including formulation and process).
(2) Please design a new dosage form of the drug with Ganaxolone as 
the active ingredient, present the designed formulation and dosage 
in a table format, and explain the rationale for the design 
(including formulation and process).
Multi-turn dialogue:
Formulation and Process Design of Compound Preparations
(1) The chemical structure of a certain API is Cc1cn2nc(-
c3cc(=O)n4cc(N5CCNC6(CC6)C5)ccc4n3)cc(C)c2n1. Please analyze this 
structure and provide its generic drug name.
(2) Analyze the physicochemical properties, structure-activity 
relationship, and pharmacological (pharmacodynamic and 
pharmacokinetic) effects of Risdiplam.
(3) Referencing the existing prescription of Risdiplam, design an 
orally disintegrating tablet formulation for it, including dosage 
based on its characteristics, and present the designed formulation 
and dosage in tabular form, explaining the design rationale.
(4) Refer to the formulation process patent (WO/US) of Risdiplam 
for the treatment of spinal muscular atrophy, describe the process 
of the new formulation, and highlight the key parameters.


3. hec_rag_pharmaceutics（药剂学综合知识库）-中文
单轮对话：
（1）影响半固体剂型溶出特征的关键因素有哪些？
（2）气体分散型剂型的优势是什么？
多轮对话：
固体分散体技术综述
（1）制备固体分散体剂型的主要目的是什么？
（2）采用固体分散体技术可使药物的溶出速率提升多少？
（3）固体分散体中溶解增强的可能机制有哪些？


4.hec_rag_pharmaceutics（药剂学综合知识库）-英文
Single-turn dialogue:
(1) What are the key factors affecting the dissolution 
characteristics of semi-solid dosage forms?
(2) What are the advantages of gas dispersion dosage forms?
Multi-turn dialogue:
Review of Solid Dispersion Technology
(1) What is the primary purpose of creating solid dispersion dosage 
forms?
      (2) How much can the dissolution rate of a drug increase when using 
      solid dispersions?
      (3) What are the possible mechanisms of enhanced dissolution in 
      solid dispersions?


 